RESUMEN
OBJECTIVE: This work aims to evaluate the therapeutic survey of adverse events during antiviral treatment of hepatitis in the three major University Hospitals in Abidjan. MATERIALS AND METHODS: A retrospective cross-sectional descriptive study of 203 patients from August 1, 2015, to July 31, 2018, enumerated adverse events during antiviral treatments, drugs used for their management, and their clinical or biological impact. RESULTS: The following was seen: hematological disorders during treatment with pegylated interferon α-2a (88.61%) and ribavirin (77.55%), pain syndrome when using pegylated interferon α-2a (90.5%), and digestive disorders while taking sofosbuvir (60.71%) and daclatasvir (66.67%). Hematological disorders were managed with filgrastim for neutropenia and oral iron or blood transfusion for anemia and/or thrombocytopenia. Pain syndrome was treated with paracetamol. As for digestive disorders, they were most often managed with activated charcoal. CONCLUSION: Correction of the adverse events was made either using causal treatment or using symptomatic drugs. However, some drugs, in particular hematopoietic factors, have been less used due to their costs.
Asunto(s)
Antivirales/efectos adversos , Hepatitis C Crónica/tratamiento farmacológico , Antivirales/uso terapéutico , Carbamatos , Côte d'Ivoire , Estudios Transversales , Quimioterapia Combinada , Genotipo , Hospitales Universitarios , Humanos , Imidazoles/efectos adversos , Imidazoles/uso terapéutico , Interferón-alfa/efectos adversos , Interferón-alfa/uso terapéutico , Polietilenglicoles/efectos adversos , Polietilenglicoles/uso terapéutico , Pirrolidinas , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/uso terapéutico , Estudios Retrospectivos , Ribavirina/efectos adversos , Ribavirina/uso terapéutico , Sofosbuvir/efectos adversos , Sofosbuvir/uso terapéutico , Resultado del Tratamiento , Valina/análogos & derivadosRESUMEN
UNLABELLED: STUDY'S AIM: This study aims a more efficient follow-up of the safety of medicines with human usage on the Ivory Coast territory. METHOD: The structure responsible for pharmacovigilance in Ivory Coast i.e. DPM listed the medicinal alerts from 2001 till 2010. RESULTS: It emerges 237 medicinal alerts among which 145 stops of marketing, 55 withdrawals of lots, 33 information notes and 4 levying of suspension of medicines. These alerts result mainly from pharmaceutical companies (49%) and the French Drug Agency or ANSM (ex-Afssaps) (43%). They mainly concern drugs of infectious target (22%) and pneumology (18%) and their motivations are so much industrial with mainly commercial reasons (27%) as of pharmacovigilance dominated by unfavorable profit/risk connections. CONCLUSION: These results constitute an important database for the survey of the medicines market in Ivory Coast and an additional motivation to accelerate the implementation of a real national center of pharmacovigilance.
Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos/organización & administración , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Farmacovigilancia , Sistemas de Registro de Reacción Adversa a Medicamentos/estadística & datos numéricos , Sistemas de Registro de Reacción Adversa a Medicamentos/tendencias , Côte d'Ivoire/epidemiología , Bases de Datos Factuales , Industria Farmacéutica/economía , Industria Farmacéutica/estadística & datos numéricos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/economía , Francia , Humanos , Comercialización de los Servicios de Salud/economía , Comercialización de los Servicios de Salud/estadística & datos numéricos , Recall y Retirada del Producto , Vigilancia de Productos Comercializados , Medición de RiesgoRESUMEN
STUDY'S AIM: This study aims a more efficient follow-up of the safety of medicines with human usage on the Ivory Coast territory. METHOD: The structure responsible for pharmacovigilance in Ivory Coast i.e. DPM listed the medicinal alerts from 2001 till 2010. RESULTS: It emerges 237 medicinal alerts among which 145 stops of marketing, 55 withdrawals of lots, 33 information notes and 4 levying of suspension of medicines. These alerts result mainly from pharmaceutical companies (49%) and the French Drug Agency or ANSM (ex-Afssaps) (43%). They mainly concern drugs of infectious target (22%) and pneumology (18%) and their motivations are so much industrial with mainly commercial reasons (27%) as of pharmacovigilance dominated by unfavorable profit/risk connections. CONCLUSION: These results constitute an important database for the survey of the medicines market in Ivory Coast and an additional motivation to accelerate the implementation of a real national center of pharmacovigilance.